Alzheimer’s Disease Treatment Market Report 2026

Alzheimer’s Disease Treatment Market Overview

• Alzheimer’s Disease Treatment market size has reached to $6.94 billion in 2025 • Expected to grow to $9.51 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Government Initiatives Fueling Growth In The Alzheimer's Disease Treatment Market • Market Trend: I Strategic Focus On Regulatory Approvals In The Alzheimer's Disease Treatment Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Alzheimer’s Disease Treatment Market?

Alzheimer’s disease treatment refers to a medication designed and developed to treat Alzheimer's. This treatment, which targets the protein beta-amyloid and is an immunotherapy, aids in the reduction of amyloid plaques, which are brain lesions connected to Alzheimer's disease. The progression of this disease causes severe memory impairment, and the person may lose the ability to carry out everyday tasks. The main types of drugs in Alzheimer’s disease treatment are cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors (also known as acetylcholinesterase inhibitors) are a class of drugs that prevent acetylcholine from being broken down normally. The different drug classes include cholinergic, memantine, combined drug, AChE inhibitors, and immunoglobulins and involve various therapeutics such as cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics.

What Is The Alzheimer’s Disease Treatment Market Growth Forecast?

The alzheimer’s disease treatment market size is expected to see strong growth in the next few years. It will grow to $9.51 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of beta-amyloid targeted immunotherapies, expansion of monoclonal antibody treatments, increasing adoption of combination therapies, growth in home care and telemedicine for alzheimer’s patients, investment in early detection and diagnostic biomarkers. Major trends in the forecast period include rising investment in immunotherapy and monoclonal antibodies, increased adoption of combination drugs targeting multiple pathways, expansion of early diagnosis and biomarker-based treatments, growing focus on cognitive function preservation and memory enhancement, integration of home-based care and remote patient monitoring for alzheimer’s.

Global Alzheimer’s Disease Treatment Market Segmentation

1) By Drug Class: Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins 2) By Drug Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists Subsegments: 1) By Cholinergic: Donepezil, Galantamine, Rivastigmine 2) By Memantine: Memantine Hydrochloride, Extended-Release Memantine 3) By Combined Drug: Donepezil and Memantine Combination 4) By AChE Inhibitors: Tacrine, Physical Inhibitors 5) By Immunoglobulins: IVIG (Intravenous Immunoglobulin), Monoclonal Antibodies

What Is The Driver Of The Alzheimer’s Disease Treatment Market?

Government initiatives are expected to propel the growth of the Alzheimer's disease treatment market. A government initiative is a plan or action taken by a government to address a specific problem or issue that can be funded by various sources, including taxes, grants, and donations. Government initiatives are used in Alzheimer's disease treatment to research projects, including clinical trials of new drugs and treatments. For instance, in April 2025, according to the American Medical Association, a US-based Professional organizations, in 2023, U.S. health spending climbed 7.5% to $4.9 trillion, or $14,570 per capita, outpacing the 4.6% increase seen in 2022. Therefore, government initiatives drive the growth of the Alzheimer's disease treatment market.

Key Players In The Global Alzheimer’s Disease Treatment Market

Major companies operating in the alzheimer’s disease treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., UCB S.A., Eisai Co. Ltd., Forest Laboratories LLC, Ono Pharmaceutical Co. Ltd., H. Lundbeck A/S, Allergan plc, Luye Pharma Group, Avanir Pharmaceuticals Inc., Denali Therapeutics Inc., Athira Pharma Inc., ProMIS Neurosciences Inc., AC Immune SA, vTv Therapeutics Inc., AB Science SA, TauRx Pharmaceuticals Ltd., Alzheon Inc.

Global Alzheimer’s Disease Treatment Market Trends and Insights

Major companies operating in the Alzheimer's disease treatment market are focusing on regulatory approvals to gain a competitive edge and enhance their product offerings. Regulatory approvals refer to the formal authorization granted by government agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), for a product to be marketed and sold to the public. For instance, in July 2024, Eli Lilly and Company, a US-based pharmaceutical company, received FDA approval for its Alzheimer's treatment, Kisunla (donanemab-azbt), which is indicated for adults with early symptomatic Alzheimer's disease, including those with mild cognitive impairment and mild dementia. The drug is administered via monthly intravenous infusion and has demonstrated efficacy in slowing the progression of the disease in clinical trials. The approval reflects its potential impact, having received Fast Track, Priority Review, and Breakthrough Therapy designations.

What Are Latest Mergers And Acquisitions In The Alzheimer’s Disease Treatment Market?

In February 2023, Lantheus Holdings Inc., a US-based provider of innovative diagnostic imaging agents and products, acquired Cerveau Technologies, Inc. for an undisclosed amount. Through this acquisition, Lantheus is expected to expand it imaging portfolio into the Alzheimer’s disease. Cerveau Technologies Inc. is a US-based provider of information and technology to researchers and clinicians.

Regional Insights

North America is the largest region in the Alzheimer’s disease treatment market in 2025. Middle East is expected to be the fastest growing region in the Alzheimer’s disease treatment market share during the forecast period. The regions covered in the alzheimer’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alzheimer’s disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Alzheimer’s Disease Treatment Market?

The Alzheimer’s disease treatment market includes revenues earned by entities by temporarily improve symptoms of memory loss and problems with thinking and reasoning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Alzheimer’s Disease Treatment Market Report 2026?

The alzheimer’s disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer’s disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.